- Home
- NUW vs VNDA Comparison
NUW vs VNDA Comparison
Compare NUW & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NUW | VNDA |
|---|---|---|
| Founded | 2008 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 254.4M | 289.0M |
| IPO Year | N/A | 2006 |
Fundamental Metrics
Financial Performance| Metric | NUW | VNDA |
|---|---|---|
| Price | $14.20 | $5.24 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $14.00 |
| AVG Volume (30 Days) | 45.3K | ★ 849.4K |
| Earning Date | 01-01-0001 | 10-29-2025 |
| Dividend Yield | ★ 3.66% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $212,074,000.00 |
| Revenue This Year | N/A | $14.32 |
| Revenue Next Year | N/A | $37.05 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 11.12 |
| 52 Week Low | $12.45 | $3.81 |
| 52 Week High | $14.44 | $5.70 |
Technical Indicators
Market Signals| Indicator | NUW | VNDA |
|---|---|---|
| Relative Strength Index (RSI) | 48.56 | 57.03 |
| Support Level | $14.12 | $4.72 |
| Resistance Level | $14.34 | $5.48 |
| Average True Range (ATR) | 0.07 | 0.29 |
| MACD | -0.01 | 0.06 |
| Stochastic Oscillator | 40.71 | 80.75 |
Price Performance
Historical ComparisonAbout NUW Nuveen AMT-Free Municipal Value Fund
Nuveen AMT-Free Municipal Value Fund is a diversified closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax by investing in a portfolio of municipal obligations. The fund predominantly invests in long-term municipal bonds, corporate bonds, short-term municipal bonds, and other assets.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.